Pangaea OncologyXMAD:PANG 63 Current Ratio is 1.78 as of Dec. 2025, which is 34% above its 10-year median of 1.33. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 53.74% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pangaea Oncology's current ratio for the quarter that ended in Dec. 2025 was 1.78.
Pangaea Oncology has a current ratio of 1.78. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pangaea Oncology's Current Ratio or its related term are showing as below:
XMAD:PANG'
s Current Ratio Range Over the Past 10 Years
Min: 0.81 Med: 1.33 Max: 4.89
Current: 1.78
During the past 13 years, Pangaea Oncology's highest Current Ratio was 4.89. The lowest was 0.81. And the median was 1.33.
XMAD:PANG's Current Ratio is ranked worse than 53.74% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs XMAD:PANG: 1.78
Pangaea Oncology (XMAD:PANG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pangaea Oncology Current Ratio Related Terms
Pangaea Oncology Current Ratio Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a Current Ratio of 1.78 as of Dec. 2025. This is 34% above median its historical median of 1.33. Over the past decade, Pangaea Oncology's Current Ratio has ranged from 0.81 to 4.89. According to the industry distribution chart, Pangaea Oncology ranks #115 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 53.7%.
Is Pangaea Oncology's Current Ratio too high?
Pangaea Oncology's current Current Ratio of 1.78 is 34% above median its 10-year median of 1.33. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 4.89. The Medical Diagnostics & Research industry median Current Ratio is 2.06. Pangaea Oncology's value of 1.78 is 13.6% below this industry median. Based on the distribution chart, Pangaea Oncology ranks #115 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #115 out of 214 companies for Current Ratio. This places Pangaea Oncology in the lower half of its industry. The industry median Current Ratio is 2.06. Pangaea Oncology's value of 1.78 is 13.6% below this benchmark. Historically, Pangaea Oncology's own Current Ratio has ranged from 0.81 to 4.89 over the past decade. While the company's 10-year median is 1.33 vs. the industry median of 2.06, Pangaea Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.06, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current Current Ratio of 1.78 is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Current Ratio is 1.78, which is 34% above median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.15, compared to a current price of €1.51 — trading 29.8% below its estimated fair value. The current Current Ratio is 1.78, which is 34% above median its 10-year median of 1.33 and 13.6% below the Medical Diagnostics & Research industry median of 2.06. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Current Ratio is 1.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.51 is trading 29.8% below its estimated GF Value™ of €2.15.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Current Ratio: 1.78 (34% above median its 10-year median of 1.33)
GF Value™: €2.15 vs. price of €1.51 (29.8% below fair value)
Industry Position: 13.6% below the Medical Diagnostics & Research median (#115 of 214)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score
Get the complete analysis for XMAD:PANG
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
